← All indications
Fetal Growth Retardation
Failure of a FETUS to attain expected GROWTH.
Drugs by status
Phase 4 trials (6)
Phase 3 trials (8)
Phase 2 trials (3)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (17)
- Novo Nordisk
- Centre Muraz
- Aarhus University
- Institute of Tropical Medicine, Belgium
- Monash University
- Laval University
- Peking University
- Royal College of Surgeons, Ireland
- University of Toulouse
- Technion University
- Government of China
- National Maternity Hospital, Ireland
- Leo Pharma
- University of Antwerp
- National University of Ireland
- Perinatal Ireland
- Chongqing Women and Children's Health Center
Organization Involved with Phase 3 Indications (23)
- Merck Serono
- Merck KGaA
- Pfizer
- Sanofi
- Fundació Sant Joan de Déu
- ZonMw: The Netherlands Organisation for Health Research and Development
- Ain Shams University
- Centre Hospitalier Intercommunal Creteil
- Johns Hopkins University
- University of British Columbia
- Leiden University
- University of Amsterdam
- Free University of Amsterdam
- Allegheny Health Network
- Perinataal Centrum MMC Veldhoven
- Isfahan University
- Hebrew University
- University of Lyon
- Friedrich Schiller University
- University of Barcelona
- Iran Ministry of Health
- University of Nantes
- International Anesthesia Research Society (IARS)
Organization Involved with Phase 2 Indications (1)
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (17)
- Bayer
- POM Wonderful LLC
- Baylor University
- Harvard University
- University of Oulu
- University of Tampere
- Utrecht University
- Centre for Fetal Programming, Denmark
- University of California, Los Angeles
- University of Colorado, Denver
- University of Copenhagen
- Emek Medical Center
- University of Sao Paulo
- University of Kuopio
- Kuopio University Hospital
- Ben Gurion University
- Washington University in St. Louis